皇氏集團(002329.SZ):公司“水牛引種項目”已列入國家“一帶一路”項目庫和中巴經濟走廊首批農業項目
格隆匯9月11日丨皇氏集團(002329.SZ)近期在接待機構投資者調研時表示,公司在巴基斯坦已建成水牛胚胎研究及生產中心,是巴基斯坦第一個能向國外出口胚胎的實驗室、巴基斯坦第一個商業胚胎實驗室;在巴基斯坦建成水牛免疫無疫牧場(一期),目前已投入使用,2023年9月該牧場正式獲批為巴基斯坦首個口蹄疫免疫無疫牧場,公司正在防城港市上思縣建設我國首個萬頭奶水牛種源智慧繁育牧場。目前,公司“水牛引種項目”已經列入國家“一帶一路”項目庫和中巴經濟走廊首批農業項目,得到了中巴兩國農業部門的高度關注和大力支持。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.